Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DM0VEC1)

Drug Name
Ergonovine Drug Info
Synonyms
Basergin; Ergobasin; Ergobasine; Ergoklinine; Ergometrin; Ergometrina; Ergometrine; Ergometrinum; Ergostetrine; Ergotocine; Ergotrate; Margonovine; Neofemergen; Secacornin; Secometrin; Ergotrate Maleate; Lysergic acid propanolamide; Ergometrina [INN-Spanish]; Ergometrine (INN); Ergometrine [INN:BAN]; Ergometrinum[INN-Latin]; D-Lysergic acid 1-hydroxymethylethylamide; D-Lysergic acid-L-propanolamide; L-Lysergic-L(beta-hydroxyisopropylamide); N-(1-(Hydroxymethyl)ethyl)-D-lysergamide; N-(alpha-(Hydroxymethyl)ethyl)-D-lysergamide; N-(2-Hydroxy-1-methylethyl)-D(+)-lysergamide; N-[(2S)-1-hydroxypropan-2-yl]-6-methyl-9,10-didehydroergoline-8beta-carboxamide; [8beta(S)]-9,10-didehydro-N-(2-hydroxy-1-methylethyl)-6-methylergoline-8-carboxamide; 9,10-Didehydro-N-(2-hydroxy-1-methylethyl)-6-methylergoline-8beta(S)-carboxamide; 9,10-Didehydro-N-(alpha-(hydroxymethyl)ethyl)-6-methylergoline-8-beta-carboxamide
Therapeutic ClassOxytocics
Cross-matching ID
PubChem CID
443884
ChEBI ID
CHEMBL119443
CAS Number
CAS 60-79-7
TTD Drug ID
D0C1IW
VARIDT Drug ID
DR00598
INTEDE Drug ID
DR0597

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
RNA transport 1.78 1.35e-1 128/186 (68.82%) EIF5;TARDBP;PNN;...
Non-homologous end-joining 1.76 8.24e-2 11/13 (84.62%) DNTT;XRCC5;MRE11;...
Glycosylphosphatidylinositol (GPI)-anchor biosynthesis 1.76 6.25e-2 20/26 (76.92%) PIGP;PIGF;GPAA1;...
Primary immunodeficiency 1.73 7.12e-2 33/38 (86.84%) BTK;ADA;CD79A;...
DNA replication 1.69 7.50e-2 34/36 (94.44%) RFC5;RFC4;MCM3;...
Vitamin digestion and absorption 1.67 8.99e-2 17/24 (70.83%) SLC5A6;LMBRD1;SLC19A2;...
Spliceosome 1.65 9.42e-2 101/150 (67.33%) SRSF5;HSPA8;PUF60;...
B cell receptor signaling pathway 1.61 1.11e-1 71/81 (87.65%) IFITM1;BTK;CD79A;...
Mismatch repair 1.53 1.82e-1 22/23 (95.65%) RFC5;RFC4;POLD1;...
Ribosome 1.50 2.28e-1 113/158 (71.52%) RPS4Y1;MRPL15;MRPS7;...
Base excision repair 1.50 2.11e-1 29/33 (87.88%) APEX1;HMGB1;POLD1;...
Maturity onset diabetes of the young 1.45 2.70e-1 21/26 (80.77%) HES1;NKX2-2;HHEX;...
Aminoacyl-tRNA biosynthesis 1.44 2.65e-1 15/66 (22.73%) GATC;NARS2;DARS2;...
Fanconi anemia pathway 1.43 2.64e-1 36/54 (66.67%) HES1;MLH1;FANCL;...
Ribosome biogenesis in eukaryotes 1.37 3.71e-1 52/108 (48.15%) HEATR1;RPP38;NOP56;...
D-Glutamine and D-glutamate metabolism 1.36 3.92e-1 5/5 (100%) GLUD2;DGLUCY
Homologous recombination 1.35 4.12e-1 35/41 (85.37%) RAD54B;POLD1;MRE11;...
Coronavirus disease 1.32 4.59e-1 215/232 (92.67%) RPS4Y1;FGB;F13A1;...
Ubiquinone and other terpenoid-quinone biosynthesis 1.32 4.49e-1 9/11 (81.82%) COQ3;HPD;NQO1;...
One carbon pool by folate 1.32 4.27e-1 15/20 (75%) AMT;DHFR;MTHFD1;...
Tight junction 1.29 4.91e-1 130/169 (76.92%) HCLS1;NEDD4;RAB13;...
Nucleotide excision repair 1.28 4.85e-1 40/47 (85.11%) MNAT1;RFC5;GTF2H3;...
Metabolism of xenobiotics by cytochrome P450 1.28 4.83e-1 49/77 (63.64%) UGT2B28;GSTM5;HSD11B1;...
Renin-angiotensin system 1.25 5.58e-1 20/23 (86.96%) ANPEP;CPA3;AGT;...
Pentose and glucuronate interconversions 1.25 5.36e-1 17/34 (50%) UGT2B28;UGT2A3;UGT2B17;...
Measles 1.20 6.52e-1 133/139 (95.68%) HSPA8;EIF3H;IKBKE;...
Cell cycle 1.20 6.34e-1 110/124 (88.71%) CDC20;CHEK1;PLK1;...
Glutathione metabolism 1.18 6.52e-1 43/57 (75.44%) ANPEP;GPX2;GSTM5;...
Influenza A 1.17 6.55e-1 156/172 (90.7%) TPSAB1;TPSB2;IKBKE;...
Fat digestion and absorption 1.16 6.50e-1 35/43 (81.4%) PLPP1;MTTP;CLPS;...
Intestinal immune network for IgA production -1.26 3.98e-1 38/48 (79.17%) CXCR4;IL15RA;HLA-DOB;...
Rheumatoid arthritis -1.26 4.04e-1 78/93 (83.87%) HLA-DOB;TLR2;ATP6V1D;...
Salivary secretion -1.31 4.07e-1 76/93 (81.72%) ATP1A3;LYZ;CHRM3;...
Transcriptional misregulation in cancer -1.37 3.95e-1 158/192 (82.29%) BAK1;ID2;IL3;...
Cushing syndrome -1.39 3.67e-1 125/155 (80.65%) CACNA1C;CYP17A1;ITPR2;...
Human cytomegalovirus infection -1.40 3.65e-1 201/225 (89.33%) SP1;PRKACB;CRK;...
Dopaminergic synapse -1.41 3.46e-1 115/132 (87.12%) AKT1;GNGT1;MAOB;...
Autoimmune thyroid disease -1.41 3.58e-1 46/53 (86.79%) HLA-DOB;IFNA6;IL2;...
Melanogenesis -1.43 3.03e-1 74/101 (73.27%) CAMK2G;PRKACB;MAP2K2;...
Oxidative phosphorylation -1.45 2.82e-1 93/133 (69.92%) NDUFAB1;NDUFA1;ATP6V1D;...
MicroRNAs in cancer -1.45 2.85e-1 146/310 (47.1%) BAK1;PDGFRA;EFNA4;...
Aldosterone synthesis and secretion -1.45 2.99e-1 85/98 (86.73%) CACNA1C;ATP2B1;ITPR2;...
Asthma -1.46 2.93e-1 25/31 (80.65%) IL3;CD40;HLA-DPA1;...
Basal cell carcinoma -1.47 2.88e-1 41/63 (65.08%) BAK1;FZD5;LEF1;...
Adrenergic signaling in cardiomyocytes -1.47 2.95e-1 130/150 (86.67%) KCNQ1;ATP1B2;ATP2A1;...
Mucin type O-glycan biosynthesis -1.47 3.09e-1 20/36 (55.56%) GALNT7;GALNT12;ST3GAL1;...
Huntington disease -1.48 3.04e-1 233/306 (76.14%) SLC1A3;NDUFB6;NDUFB7;...
Gastric acid secretion -1.50 3.01e-1 63/76 (82.89%) CAMK2G;PRKACB;KCNK10;...
Parkinson disease -1.50 3.25e-1 176/249 (70.68%) NDUFAB1;MAOB;PINK1;...
Central carbon metabolism in cancer -1.51 3.23e-1 67/70 (95.71%) LDHA;MAP2K2;SLC16A3;...
Retrograde endocannabinoid signaling -1.53 3.03e-1 118/148 (79.73%) GNGT1;NDUFAB1;CACNA1C;...
Viral myocarditis -1.54 2.86e-1 53/60 (88.33%) LAMA1;FYN;CASP9;...
Renal cell carcinoma -1.55 2.92e-1 68/69 (98.55%) RAF1;BAD;VEGFA;...
Amphetamine addiction -1.58 2.61e-1 57/69 (82.61%) MAOB;SIRT1;CACNA1C;...
Mitophagy -1.62 2.19e-1 56/68 (82.35%) MAPK8;TBK1;CSNK2B;...
Cocaine addiction -1.63 2.46e-1 42/49 (85.71%) PRKACB;GRM3;CREB5;...
Axon guidance -1.64 2.89e-1 151/182 (82.97%) PPP3R1;PAK2;RGS3;...
Cardiac muscle contraction -1.67 2.64e-1 64/87 (73.56%) SLC9A1;ATP2A2;COX6A2;...
Allograft rejection -1.73 2.25e-1 32/38 (84.21%) IL2;HLA-DRB1;FAS;...
Ferroptosis -1.89 6.09e-2 36/41 (87.8%) SLC3A2;SAT1;GPX4;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 10uM 6H, 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HT-29 CVCL_0320 Homo sapiens 10uM 6H
Hematopoietic system
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
ASC CVCL_U602 Homo sapiens 10uM 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 10uM 6H, 24H
Liver
Hepatoblastoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Hep G2 CVCL_0027 Homo sapiens 10uM 6H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 10uM 6H, 24H
Non-small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HCC515 CVCL_5134 Homo sapiens 10uM 6H, 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 10uM 6H, 24H
VCaP CVCL_2235 Homo sapiens 10uM 6H, 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 10uM 6H